2-(4-(methanesulfonoamidomethyl)phenyl)acetic acid | 110626-68-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-(methanesulfonoamidomethyl)phenyl)acetic acid
• 英文别名: 4-[[(methylsulphonyl)amino]methyl]benzeneacetic acid；[4-(methanesulfonylamino-methyl)-phenyl]-acetic acid；2-[4-(methanesulfonamidomethyl)phenyl]acetic acid
• CAS: 110626-68-1
• 化学式: C₁₀H₁₃NO₄S
• 分子量: 243.284
• InChiKey: GEFDVUXXHBTWPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-(methanesulfonoamidomethyl)phenyl)acetic acid 、 (2S,3s)-1-(2-甲基氨基-2-苯基-乙基)-吡咯烷-3-醇 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 生成 N-[(S)-2-((S)-3-Hydroxy-pyrrolidin-1-yl)-1-phenyl-ethyl]-2-[4-(methanesulfonylamino-methyl)-phenyl]-N-methyl-acetamide
  参考文献：
  名称：

  Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

  摘要：

  Some K opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 mu M) while displaying high affinity toward the cloned human K opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.020
• 作为产物：
  描述：

  4-溴苯乙酸甲酯 在 palladium on activated charcoal 盐酸 、 lithium hydroxide 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、482.63 kPa 条件下， 生成 2-(4-(methanesulfonoamidomethyl)phenyl)acetic acid
  参考文献：
  名称：

  Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

  摘要：

  Some K opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 mu M) while displaying high affinity toward the cloned human K opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.020

文献信息

• 一种谷氨酰酶抑制剂及其组合物和用途
  申请人：北京赛林泰医药技术有限公司

  公开号：CN107474024B

  公开（公告）日：2022-12-13

  本发明提供了式I表示的一系列含杂环化合物，其具有谷氨酰胺酶抑制活性，并可用于治疗与谷氨酰胺酶功能异常或谷氨酰胺酶活性升高相关的疾病和病状。
• Sulfonylamino phenylacetamide derivatives and methods of their use
  申请人：——

  公开号：US20040254156A1

  公开（公告）日：2004-12-16

  Sulfonylamino phenylacetamide derivatives of the general formula 1 are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to &kgr; opioid receptors; (2) display good opioid receptor selectivity of &kgr; versus &mgr; and &kgr; versus &dgr;; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.

  揭示了通式1的磺酰氨基苯乙酰胺衍生物。还公开了含有这些化合物的药物组合物和它们的使用方法。在某些实施例中，本发明的化合物最好具有以下特征：(1) 与κ阿片受体结合的亲和力高；(2) 在κ与μ受体以及κ与δ受体之间显示良好的阿片受体选择性；以及(3) 不显著抑制细胞色素P450酶的活性，特别是CYP2D6、CYP2C9和CYP3A4。
• Indole derivatives
  申请人：Glaxo Group Limited

  公开号：US04855314A1

  公开（公告）日：1989-08-08

  Compounds are disclosed of formula (I): ##STR1## wherein R.sub.1 is halogen, a C.sub.1-3 alkoxy, R.sub.6 R.sub.7 NCO(CH.sub.2).sub.p --, R.sub.6 CONH(CH.sub.2).sub.p --, R.sub.6 R.sub.7 NSO.sub.2 (CH.sub.2).sub.p --, or R.sub.8 SO.sub.2 NH(CH.sub.2).sub.p -- (where R.sub.6 and R.sub.7 each represents hydrogen or C.sub.1-3 alkyl, R.sub.8 represents C.sub.1-3 alkyl and p is zero or 1); R.sub.2 represents hydrogen or C.sub.1-3 alkyl; R.sub.3 represents hydrogen or C.sub.1-3 alkyl; R.sub.4 and R.sub.5 each represents hydrogen, C.sub.1-3 alkyl or 2-propenyl; A represents --CO-- or --SO.sub.2 --; n represents an integer from 2 to 5; and m represents zero or an integer from 1 to 4; and physiologically acceptable salts and solvates (e.g. hydrates) thereof. The compounds have potent and selective vasoconstrictor activity and are indicated as useful for the treatment of migraine. The compounds may be formulated as pharmaceutical compositions with physiologically acceptable carriers or excipients for administration by any convenient route. Various methods for the preparation of the compounds (I) are disclosed.

  公式（I）的化合物被揭示，其中R1为卤素，C1-3烷氧基，R6R7NCO（CH2）p--，R6CONH（CH2）p--，R6R7NSO2（CH2）p--或R8SO2NH（CH2）p--（其中R6和R7分别表示氢或C1-3烷基，R8表示C1-3烷基，p为零或1）；R2表示氢或C1-3烷基；R3表示氢或C1-3烷基；R4和R5分别表示氢，C1-3烷基或2-丙烯基；A表示--CO--或--SO2--；n表示从2到5的整数；m表示零或从1到4的整数；以及其生理上可接受的盐和溶剂（例如水合物）。这些化合物具有强效和选择性的血管收缩作用，并被指示用于治疗偏头痛。这些化合物可以与生理上可接受的载体或赋形剂一起制成药物组成物，以便通过任何方便的途径进行给药。还揭示了制备化合物（I）的各种方法。
• Indole derivatives having a selective vasoconstrictor activity
  申请人：GLAXO GROUP LIMITED

  公开号：EP0240096A1

  公开（公告）日：1987-10-07

  Compounds are disclosed of formula (I): wherein R, represents halogen, C1 3 alkoxy, or a group R6R7NCO(CH2)p-, R6CONH(CH2)P-, R6R7NSO2(CH2)p-, or R8SO2NH(CH2)p - (where R6 and R7, each independently represents hydrogen or C, 3 alkyl, Ra represents C1 3 alkyl and p is zero or 1); R2 represents hydrogen or C, 3 alkyl; R3 represents hydrogen or C, 3 alkyl; R4 and R5 each independently represents hydrogen, a C1 3 alkyl or a 2-propenyl group; A represents -CO- or -SO2-; n represents an integer from 2 to 5; an m represents zero or an integer from 1 to 4; and physiologically acceptable salts and solvates (e.g. hydrates) thereof. The compounds have potent and selective vasoconstrictor activity and are indicated as useful for the treatment of migraine. The compounds may be formulated as pharmaceutical compositions with pharmaceutically acceptable carriers or excipients for administration by any suitable means. Various methods for the preparation of the compounds are disclosed.

  公开了式(I)化合物： 其中 R 代表卤素、C1 3 烷氧基或一个基团 R6R7NCO(CH2)p-, R6CONH(CH2)P-, R6R7NSO2(CH2)p-、 或 R8SO2NH（CH2）p-（其中 R6 和 R7 各自独立地代表氢或 C，3 烷基，Ra 代表 C1 3 烷基，p 为 0 或 1）； R2 代表氢或 C，3 烷基； R3 代表氢或 C，3 烷基； R4 和 R5 各自独立地代表氢、 C1 3 烷基或 2-丙烯基； A 代表-CO-或-SO2-； n 代表 2 至 5 的整数；m 代表零或 1 至 4 的整数；及其生理上可接受的盐和溶液（如水合物）。 这些化合物具有强效和选择性血管收缩活性，可用于治疗偏头痛。这些化合物可与药学上可接受的载体或赋形剂配制成药物组合物，以任何合适的方式给药。公开了制备这些化合物的各种方法。
• US4855314A
  申请人：——

  公开号：US4855314A

  公开（公告）日：1989-08-08